Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.07.22	Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022 (PR Newswire)
01.07.22	Regeneron Completes Acquiring Sanofi's Stake In Libtayo (RTTNews)
01.07.22	Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab) (PR Newswire)
29.06.22	Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review (RTTNews)
29.06.22	EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review (PR Newswire)
28.06.22	Biotech Stocks Facing FDA Decision In July 2022 (RTTNews)
24.06.22	NTLA : Study Of NTLA-2001 On Transthyretin Amyloidosis Shows Serum TTR Reductions Remained Durable (RTTNews)
24.06.22	Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions ... (PR Newswire)
09.06.22	Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran (RTTNews)
08.06.22	Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis (RTTNews)
07.06.22	FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis (PR Newswire)
02.06.22	Sanofi- und Regeneron-Aktien schwächer: Regeneron zahlt Sanofi für Anteil an Krebsmedikament Libtayo Millionenbetrag (Dow Jones) Regeneron Pharmaceuticals übernimmt den Anteil seines Partners Sanofi am Anti-PD-1-Krebsmedikament Libtayo.» mehr
02.06.22	Regeneron To Acquire Global Rights To Libtayo From Sanofi For $900 Mln, Plus Royalties (RTTNews)
02.06.22	Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of ... (PR Newswire)
31.05.22	Regeneron Completes Acquisition of Checkmate Pharmaceuticals (PR Newswire)
31.05.22	Regeneron : FDA Accepts Dupixent For Priority Review In Adults With Prurigo Nodularis (RTTNews)
31.05.22	FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis (PR Newswire)
31.05.22	Tender offer statement by Third Party (RSS)
27.05.22	Biotech Stocks Facing FDA Decision In June 2022 (RTTNews)
23.05.22	FDA Approves Regeneron's Dupixent To Treat Eosinophilic Esophagitis (RTTNews)
21.05.22	Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol (PR Newswire)
20.05.22	FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis (PR Newswire)
20.05.22	Tender offer statement by Third Party (RSS)
17.05.22	Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur (PR Newswire)
13.05.22	High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair (PR Newswire)
13.05.22	High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair (PR Newswire)
11.05.22	Tender offer statement by Third Party (RSS)
04.05.22	Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates (RTTNews)
04.05.22	Regeneron Reports First Quarter 2022 Financial and Operating Results (PR Newswire)
03.05.22	Ausblick: Regeneron Pharmaceuticals präsentiert Quartalsergebnisse (finanzen.net)
02.05.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
02.05.22	Form SC TO-T 872589 (RSS)
21.04.22	Form DEFA14A 872589 (RSS)
19.04.22	Regeneron Pharma To Buy Checkmate Pharmaceuticals In $250 Mln All Cash Deal (RTTNews)
19.04.22	SpringWorks, Regeneron To Evaluate Nirogacestat In Combination With REGN5458 In Multiple Myeloma (RTTNews)
19.04.22	Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types (PR Newswire)
19.04.22	Erste Schätzungen: Regeneron Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
19.04.22	Form SC TO-C 872589 (RSS)
14.04.22	Regeneron Says FDA Extends Review Of BLA For REGEN-COV By 3 Months (RTTNews)
14.04.22	U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19 (PR Newswire)
11.04.22	Form 4 872589 (RSS)
07.04.22	Regeneron, Sanofi: EU Approves Dupixent For Children Aged 6 To 11 Years With Severe Asthma (RTTNews)
07.04.22	Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation (PR Newswire)
05.04.22	Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 (PR Newswire)
04.04.22	Regeneron : FDA Accepts Dupixent For Priority Review In Patients Aged 12 Yrs And Older With EoE (RTTNews)
04.04.22	FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis (PR Newswire)
30.03.22	Form 4 872589 (RSS)
28.03.22	Biotech Stocks Facing FDA Decision In April 2022 (RTTNews)
26.03.22	Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis (PR Newswire)
18.03.22	Form 4 872589 (RSS)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
19.12.24		Optimismus in New York: NASDAQ 100 startet im Plus
17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

24.12.24

Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu

24.12.24

Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone

19.12.24

Optimismus in New York: NASDAQ 100 startet im Plus

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten